TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
BUFFALO, NY- October 11, 2024 – A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Transplant or no transplant for TP53 mutated AML.” As highlighted in this ...
Continuous and fixed-duration ibrutinib-based regimens deliver survival outcomes for CLL patients comparable to an age-matched European population. The study supports current CLL treatment ...
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback